Free shipping on all orders over $ 500

BTK inhibitor 1 (Compound 27)

Cat. No. M20631
BTK inhibitor 1 (Compound 27) Structure
Size Price Availability
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

BTK inhibitor 1 (compound 27) is an inhibitor of BTK with an IC50 of 0.11 nM for Btk and inhibits B cell activation in hWB with an IC50 of 2 nM.

Chemical Information
Molecular Weight 474.49
Formula C24H23FN8O2
CAS Number 2230724-66-8
Solubility (25°C) DMSO 95 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Soňa Krajčovičov, et al. Eur J Med Chem. 1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton's tyrosine kinase

[2] Jeffrey A Jones, et al. Lancet Oncol. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

[3] Philip A Thompson, et al. Expert Opin Investig Drugs. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)

[4] Sobhana Babu Boga, et al. Bioorg Med Chem Lett. Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritis

[5] Xiaolei Gao, et al. Bioorg Med Chem Lett. Discovery of novel BTK inhibitors with carboxylic acids

Related BTK Products
BCPyr

BCPyr is a new candidate BTK degradation agent (DC50 = 800 nM).

BMS-986143

BMS-986143 is a potent, reversible inhibitor of tyrosine kinase (BTK), which has been successfully targeted by a number of irreversible tumor compounds.

BIIB091

The reversible BTK kinase inhibitor BIIB091 is a highly selective phase I clinical candidate compound for multiple sclerosis.

TAK-020

TAK-020 is a highly selective oral covalent BTK inhibitor with a promising safety and tolerability profile for both hematologic malignancies and autoimmune diseases.

WYE-175837

WYE-175837 is a BTK inhibitor

  Catalog
Abmole Inhibitor Catalog




Keywords: BTK inhibitor 1 (Compound 27) supplier, BTK, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.